Get to know our clinical trials
Prolongation clinical trial for the provision of continuous treatment to patients with blood malignancies previously enrolled in studies with tafasitamab.
THE OBJECTIVE OF THE STUDY IS TO PROVIDE CONTINUED TREATMENT WITH TAFASITAMAB TO PATIENTS ENROLLED IN PREVIOUS RESEARCH STUDIES THAT WILL BE CLOSED, AND TO PATIENTS WHO DO NOT HAVE ACCESS TO THE COMMERCIALLY AVAILABLE DRUG. IN ADDITION, THE SAFETY OF THE STUDY DRUG IN TREATED PATIENTS WILL CONTINUE TO BE MONITORED.
Technical Summary
- A MULTICENTER, OPEN-LABEL, EXTENSION STUDY FOR THE PROVISION OF CONTINUOUS TREATMENT TO PATIENTS WITH BLOOD MALIGNANCIES PREVIOUSLY ENROLLED IN STUDIES WITH TAFASITAMAB. IMMUNOTHERAPY.
- Code EudraCT: 2022-500765-27-00
- Protocol number: MOR208C216
- Promoter: MorphoSys AG
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.